1211580-54-9

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-2-(difluoromethyl)pyridine is used as a building block for the synthesis of various biologically active compounds. Its unique structure allows for the development of new pharmaceutical agents with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 4-Bromo-2-(difluoromethyl)pyridine serves as a key intermediate in the production of pesticides. Its incorporation into these compounds can enhance their effectiveness in controlling pests and diseases in agriculture.
Used as an Intermediate in Organic and Medicinal Chemistry:
4-Bromo-2-(difluoromethyl)pyridine is utilized as an intermediate in the synthesis of other organic and medicinal chemicals. Its presence in these compounds can contribute to their chemical properties and potential applications in various fields.
Safety Precautions:
Due to its potential toxicity if ingested or inhaled, 4-Bromo-2-(difluoromethyl)pyridine should be handled with proper safety measures in a controlled laboratory environment. This ensures the protection of both the individuals working with the compound and the integrity of the experiments being conducted.

Upstream product

• 131747-63-2 4-bromo-2-pyridinecarboxaldehyde 

Downstream Products

• 1227163-02-1 1-(3-Bromophenyl)-1-(2-(difluoromethyl)pyridin-4-yl)-4-fluoro-1H-isoindol-3-amine 
• 1256818-14-0 2-(difluoromethyl)isonicotinic acid 
• 1251844-44-6 methyl 2-(difluoromethyl)isonicotinate 
• 1446509-58-5 2-(difluoromethyl)pyridin-4-amine 

Relevant academic research and scientific papers

Tricyclic dihydroimidazopyrimidinone derivative, and preparation method, pharmaceutical composition and application thereof

The invention provides a compound as shown in a general formula (I), cis-trans isomers, enantiomers, diastereoisomers, racemes, solvates, hydrates or pharmaceutically acceptable salts or prodrugs of the compound, a preparation method of the compound, a pharmaceutical composition containing the compound and an application of the compound as aLp-PLA2 inhibitor, wherein R1, R2, Rx, Ra, Q, U, X, Y, m, n and A are defined in the specification.

BACE1 INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE

Compounds, pharmaceutical compositions containing the same useful in the treatment of Alzheimer's disease are disclosed. Methods of preparing the compounds and compositions and use thereof are also disclosed.

SPIROCYCLIC COMPOUNDS

Disclosed herein are spirocyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.

SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS

The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS

The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

NOVEL COMPOUNDS

Disclosed are novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

NEW COMPOUNDS 578

The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.